Skip to main content
Journal cover image

Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.

Publication ,  Journal Article
Apolo, AB; Ostrovnaya, I; Halabi, S; Iasonos, A; Philips, GK; Rosenberg, JE; Riches, J; Small, EJ; Milowsky, MI; Bajorin, DF
Published in: J Natl Cancer Inst
April 3, 2013

A prognostic model that predicts overall survival (OS) for metastatic urothelial cancer (MetUC) patients treated with cisplatin-based chemotherapy was developed, validated, and compared with a commonly used Memorial Sloan-Kettering Cancer Center (MSKCC) risk-score model. Data from 7 protocols that enrolled 308 patients with MetUC were pooled. An external multi-institutional dataset was used to validate the model. The primary measurement of predictive discrimination was Harrell's c-index, computed with 95% confidence interval (CI). The final model included four pretreatment variables to predict OS: visceral metastases, albumin, performance status, and hemoglobin. The Harrell's c-index was 0.67 for the four-variable model and 0.64 for the MSKCC risk-score model, with a prediction improvement for OS (the U statistic and its standard deviation were used to calculate the two-sided P = .002). In the validation cohort, the c-indices for the four-variable and the MSKCC risk-score models were 0.63 (95% CI = 0.56 to 0.69) and 0.58 (95% CI = 0.52 to 0.65), respectively, with superiority of the four-variable model compared with the MSKCC risk-score model for OS (the U statistic and its standard deviation were used to calculate the two-sided P = .02).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

April 3, 2013

Volume

105

Issue

7

Start / End Page

499 / 503

Location

United States

Related Subject Headings

  • Urothelium
  • Treatment Outcome
  • Survival Analysis
  • Prognosis
  • Predictive Value of Tests
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Nomograms
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Apolo, A. B., Ostrovnaya, I., Halabi, S., Iasonos, A., Philips, G. K., Rosenberg, J. E., … Bajorin, D. F. (2013). Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst, 105(7), 499–503. https://doi.org/10.1093/jnci/djt015
Apolo, Andrea B., Irina Ostrovnaya, Susan Halabi, Alexia Iasonos, George K. Philips, Jonathan E. Rosenberg, Jamie Riches, Eric J. Small, Matthew I. Milowsky, and Dean F. Bajorin. “Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.J Natl Cancer Inst 105, no. 7 (April 3, 2013): 499–503. https://doi.org/10.1093/jnci/djt015.
Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, et al. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013 Apr 3;105(7):499–503.
Apolo, Andrea B., et al. “Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.J Natl Cancer Inst, vol. 105, no. 7, Apr. 2013, pp. 499–503. Pubmed, doi:10.1093/jnci/djt015.
Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013 Apr 3;105(7):499–503.
Journal cover image

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

April 3, 2013

Volume

105

Issue

7

Start / End Page

499 / 503

Location

United States

Related Subject Headings

  • Urothelium
  • Treatment Outcome
  • Survival Analysis
  • Prognosis
  • Predictive Value of Tests
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Nomograms
  • Middle Aged
  • Male